Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
Stifel Downgrades HilleVax to Hold From Buy, Adjusts Price Target to $3 From $34
HilleVax, Inc: Hold Rating Justified by Clinical Trial Setbacks and Strategic Uncertainties
Hold Rating on HilleVax as Clinical Setbacks Complicate Investment Outlook
Analysts Conflicted on These Healthcare Names: HilleVax, Inc (HLVX), UnitedHealth (UNH) and Morphic Holding (MORF)
HilleVax Analyst Ratings
HilleVax Analyst Ratings
HilleVax Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating
HC Wainwright & Co. Reiterates Buy on HilleVax, Maintains $28 Price Target
HilleVax Analyst Ratings
HilleVax, Inc's HIL-214 Vaccine Candidate Promises Broad Protection Against Norovirus, Justifying Buy Rating
HilleVax Analyst Ratings
Guggenheim Maintains Buy on HilleVax, Lowers Price Target to $34
HilleVax Analyst Ratings
Analysts Offer Insights on Healthcare Companies: HilleVax, Inc (HLVX), Akoya Biosciences (AKYA) and Clinigence Holdings (NUTX)
Positive Financial Outlook and High Probability of Success Bolster Buy Rating for HilleVax, Inc: An Analyst Recommendation Report
Stifel Maintains Buy on HilleVax, Lowers Price Target to $30
HilleVax Analyst Ratings
No Data